This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -80.00% and -70.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Applied Genetic Stock Up on Favorable Eye Therapy Study Data
by Zacks Equity Research
Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
by Zacks Equity Research
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
by Ekta Bagri
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
by Zacks Equity Research
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
by Zacks Equity Research
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.
ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. RGNX: Which Stock Is the Better Value Option?
Implied Volatility Surging for REGENXBIO (RGNX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
ALXN or RGNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?